辅助TACE对合并微血管侵犯肝细胞癌生存的影响:里程碑分析
这项回顾性多中心研究纳入512例合并微血管侵犯(MVI)的肝细胞癌(HCC)根治性切除患者,采用倾向性评分匹配及里程碑分析、时间依赖Cox回归校正永生时间偏倚,评估辅助经导管动脉化疗栓塞(TACE)的真实生存价值。校正后辅助TACE与总生存改善相关但不改善无复发生存,在肿瘤≥5 cm亚组中总生存与无复发生存均获益。
要点
- 辅助TACE与合并MVI的HCC根治术后总生存改善相关,但不改善无复发生存。
- 肿瘤≥5 cm的MVI患者中,辅助TACE与总生存和无复发生存均改善相关。
- 常规生存分析高估辅助TACE获益,需用里程碑分析或时间依赖模型校正永生时间偏倚。
核心结论
- 辅助TACE与合并MVI的HCC患者总生存改善相关,尤其肿瘤≥5 cm高危患者总生存和无复发生存均持续改善。
- 肿瘤≥5 cm的MVI患者中辅助TACE的潜在获益可能超出常规术后早期时间窗。
研究设计与样本
- 回顾性多中心研究,纳入2018至2024年间512例接受根治性肝切除伴或不伴辅助TACE的合并MVI的HCC患者。
- 采用倾向性评分匹配平衡基线特征,并行2、4、6、12个月里程碑分析及时间依赖Cox回归校正永生时间偏倚。
主要发现
- 全队列常规Kaplan-Meier分析显示TACE组总生存和无复发生存均优于非TACE组(均p < 0.05)。
- 里程碑分析显示4、6、12个月里程碑总生存改善(HR分别为0.68、0.70、0.69),无复发生存仅在6个月里程碑差异显著(p = 0.020)。
- 时间依赖Cox分析显示辅助TACE与总生存改善相关(HR 0.63,95% CI 0.47-0.85,p = 0.002),但与无复发生存无关。
- 肿瘤≥5 cm亚组里程碑分析显示总生存和无复发生存均显著获益(均p < 0.05)。
- 肿瘤≥5 cm亚组时间依赖Cox分析显示辅助TACE与总生存改善(HR 0.46,95% CI 0.30-0.69,p < 0.001)及无复发生存改善(HR 0.66,95% CI 0.47-0.92,p = 0.014)相关。
临床怎么用
- 对合并MVI的HCC根治术后患者,可考虑辅助TACE以改善总生存,尤其肿瘤≥5 cm的高危患者可能同时改善无复发生存。
- 评估辅助TACE疗效时应关注治疗时机并采用里程碑分析或时间依赖模型校正永生时间偏倚,避免常规分析高估获益。
局限性
- 本研究为回顾性设计,尽管采用倾向性评分匹配和时间依赖分析,仍可能存在未测量混杂。
- 辅助TACE的获益可能受治疗时机影响,研究结果需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognostic significance of adjuvant transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI) remains controversial. Furthermore, current literature often overlooks the treatment timing, and conventional survival analyses fail to address the immortal time bias introduced by delayed TACE initiation. This study aimed to evaluate the true clinical value of adjuvant TACE after adjusting for this bias. METHODS: This retrospective multicenter study included 512 HCC patients with MVI who underwent curative hepatectomy with or without adjuvant TACE between 2018 and 2024. Propensity score matching (PSM) was used to balance baseline characteristics. To rigorously adjust for immortal time bias, landmark analysis at 2-, 4-, 6-, and 12-month after surgery, along with time-dependent Cox regression (TDC) analysis, was performed. RESULTS: In the entire cohort, conventional Kaplan-Meier analysis showed better overall survival (OS) and recurrence-free survival (RFS) in the TACE group than in the NO-TACE group (all p < 0.05). However, landmark analysis showed improved OS at the 4-, 6-, and 12-month landmarks (HR 0.68, 0.70, 0.69, respectively), whereas RFS differed significantly only at the 6-month landmark (p = 0.020). TDC analysis showed that adjuvant TACE was associated with improved OS (HR 0.63, 95% CI 0.47-0.85, p = 0.002) but not RFS. In the subgroup with tumor size ≥ 5 cm, landmark analysis showed significant advantages in both OS and RFS (all p < 0.05), and TDC analysis further revealed that adjuvant TACE was linked to improved OS (HR 0.46, 95% CI 0.30-0.69, p < 0.001) and RFS (HR 0.66, 95% CI 0.47-0.92, p = 0.014). CONCLUSION: Adjuvant TACE was associated with improved OS in HCC patients with MVI, particularly in high-risk patients with tumor size ≥ 5 cm, who showed consistent improvements in both OS and RFS. The potential benefit of adjuvant TACE may extend beyond the conventional early postoperative period in MVI patients with tumor size ≥ 5 cm.
引用
- Zhang TC, Jia WL, Cao Y, et al. Effect of adjuvant transarterial chemoembolization on survival in hepatocellular carcinoma with microvascular invasion: a landmark analysis. Surg Endosc. 2026. PMID: 42257955. doi:10.1007/s00464-026-12838-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。